Skip to main content

Table 2 Meta-analysis of the APOB rs17240441 polymorphism with plasma APOB and lipid levels

From: Associations of the APOB rs693 and rs17240441 polymorphisms with plasma APOB and lipid levels: a meta-analysis

Groups or subgroups

Comparisons (Subjects)

P Heterogeneity

SMD (95% CI)

P SMD

APOB

 All

15 (5047)

0.27

0.13 (0.06–0.20)

< 0.01

 Studies in HWE

12 (4192)

0.32

0.11 (0.04–0.19)

< 0.01

 Caucasian

8 (3626)

0.31

0.12 (0.03–0.21)

< 0.01

 Asian

6 (1264)

0.18

0.14 (−0.01–0.30)

0.07

 CHD

5 (2841)

0.86

0.11 (0.03–0.18)

< 0.01

 Healthy or control

9 (1975)

0.06

0.12 (−0.03–0.26)

0.11

 Case-control studies

8 (3951)

0.29

0.13 (0.04–0.21)

< 0.01

 Cohort studies

7 (1096)

0.23

0.15 (−0.001–0.30)

0.05

TG

 All

29 (7411)

< 0.01

0.03 (−0.04–0.11)

0.37

 Studies in HWE

24 (6576)

0.02

0.04 (−0.05–0.12)

0.44

 Male

6 (3215)

0.14

0.11 (−0.01–0.24)

0.08

 Female

4 (411)

0.16

0.22 (−0.10–0.53)

0.18

 Caucasian

12 (4691)

0.11

0.02 (−0.11–0.07)

0.62

 Asian

11 (1281)

0.13

0.21 (0.06–0.36)

< 0.01

 CHD

8 (3138)

0.02

0.15 (−0.01–0.32)

0.07

 Healthy or control

18 (3274)

0.04

−0.02 (−0.13–0.08)

0.70

 Case-control studies

15 (4538)

0.12

0.09 (−0.003–0.18)

0.06

 Cohort studies

14 (2873)

0.03

0.03 (−0.04–0.11)

0.60

TC

 All

32 (7875)

< 0.01

0.17 (0.07–0.26)

< 0.01

 Studies in HWE

23 (6133)

< 0.01

0.18 (0.04–0.33)

0.01

 Male

7 (3220)

0.72

0.14 (0.07–0.21)

< 0.01

 Female

5 (470)

< 0.01

0.74 (−0.26–1.75)

0.15

 Caucasian

14 (4598)

0.34

0.13 (0.06–0.20)

< 0.01

 Asian

13 (1924)

< 0.01

0.33 (0.06–0.60)

0.02

 CHD

10 (3455)

0.42

0.12 (0.05–0.19)

< 0.01

 Healthy or control

15 (2577)

< 0.01

0.23 (0.05–0.40)

0.01

 Case-control studies

14 (4526)

< 0.01

0.22 (0.03–0.41)

0.02

 Cohort studies

18 (3349)

0.15

0.14 (0.05–0.23)

< 0.01

LDL-C

 All

30 (5658)

< 0.01

0.15 (0.07–0.23)

< 0.01

 Studies in HWE

23 (4233)

< 0.01

0.15 (0.04–0.25)

< 0.01

 Male

5 (955)

0.85

0.07 (−0.06–0.21)

0.27

 Female

4 (411)

0.04

0.01 (−0.38–0.41)

0.95

 Caucasian

13 (2562)

0.38

0.14 (0.05–0.23)

< 0.01

 Asian

12 (1817)

< 0.01

0.18 (0.00–0.35)

0.05

 CHD

7 (879)

0.09

0.15 (−0.04–0.34)

0.12

 Healthy or control

19 (3764)

< 0.01

0.13 (0.02–0.24)

0.02

 Case-control studies

15 (2807)

0.07

0.12 (0.02–0.23)

0.03

 Cohort studies

15 (2851)

< 0.01

0.18 (0.06–0.31)

< 0.01

HDL-C

 All

27 (5124)

< 0.01

−0.04 (−0.12–0.05)

0.40

 Studies in HWE

21 (3750)

< 0.01

−0.07 (−0.18–0.05)

0.25

 Male

5 (703)

0.10

−0.06 (−0.30–0.17)

0.58

 Female

4 (411)

0.57

−0.01 (−0.23–0.21)

0.91

 Caucasian

9 (1881)

0.30

−0.02 (−0.13–0.09)

0.77

 Asian

13 (1924)

< 0.01

−0.10 (−0.26–0.06)

0.21

 CHD

7 (879)

0.05

−0.06 (−0.27–0.14)

0.55

 Healthy or control

18 (3605)

0.01

−0.03 (−0.13–0.08)

0.65

 Case-control studies

13 (2267)

0.02

−0.07 (−0.20–0.06)

0.31

 Cohort studies

14 (2854)

0.06

−0.01 (−0.12–0.10)

0.89

  1. SMD standardized mean difference, 95% CI 95% confidence interval, HWE Hardy-Weinberg equilibrium, APOB apolipoprotein B, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol